Abiraterone Acetate for nmCRPC, The Forgotten Dance Partner? - Zach Klaassen and Chris Wallis

Zach Klaassen and Chris Wallis discuss a jointly published paper that was published in Jama Oncology, November, titled, “Abiraterone Acetate for Nonmetastatic Castration-Resistant Prostate Cancer, The Forgotten Dance Partner?” They reference recent trials in this space and discuss cost and other variables to consider when making a therapeutic decision.

Biographies:
Zachary Klaassen, MD, MSc, Urologic Oncologist, Assistant Professor Surgery/Urology at the Medical College of Georgia at Augusta University, Georgia Cancer Center

Christopher J.D. Wallis is a Urology Resident at the University of Toronto. He obtained his Doctor of Medicine from the University of British Columbia and his Doctor of Philosophy in Clinical Epidemiology and Health Care Research from the Institute of Health Policy, Management, and Evaluation at the University of Toronto.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe